



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN : L85195MP1988PLC004446

14th August, 2019

To,
Listing Department,
BSE Limited.
Rotunda Building, P J Towers
Dalal Street, Fort,
Mumbai – 400 001

To,
Listing Department,
National Stock Exchange of India Limited.
'Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai – 400 051

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Reference: Scrip Code: ALPA ; ISIN: INE385101010

Dear Sir/ Madam,

This is with reference to our letter dated 2nd August, 2019 in relation to the intimation of board meeting; this is to inform you that the Board of Directors of the Company at its meeting held today at 4.00 p.m. at registered office of the Company situated at 33/2, A.B. Road Pigdamber Rao, Indore MP 453446 IN. The Board inter-alia has approved the following matter:

1. Approval of the Unaudited Standalone & Consolidated Financial Results of the Company along with Auditor's Limited Review Report for quarter ended on 30th June, 2019.
2. Approval of the Notice of 31st Annual General Meeting of the Company.

This is for the information and record of the exchange and members thereof;

You are requested to take the same on records.

For ALPA LABORATORIES LIMITED

Paresh Chawla
Managing Director
DIN- 00520411






INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON STANDALONE & CONSOLIDATED QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF THE SEBI LODR REGULATIONS, 2015

To the Board of Directors of **ALPA LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited Standalone & Consolidated financial results of **ALPA LABORATORIES LIMITED** for the quarter ended **June 30, 2019**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
Anuradha Ratnaparkhi & Associates
Chartered Accountants

Firm Registration No.023451C


Anuradha Ratnaparkhi
Proprietor

Membership Number: 075412

UDIN: 19075412AAAAAH2986

Date: 14th August, 2019.

Place: Indore

Submission of Standalone and Consolidated Financial Results for Quarter ended on 30th June 2019					(Rs. In Lacs) Except EPS	
Particulars	Consolidated Results		Standalone Results			
	Quarter Ended		Quarter Ended		Year Ended	
	3 months ended (30-06-2019)	3 months ended (30-06-2019)	Preceding 3 months ended (31-03-2019)	Corresponding 3 months ended in the previous year (30-06-2018)	Previous year ended (31-03-2019)	
	Unaudited	Unaudited	Audited	Unaudited	Audited	
Refer Notes Below						
1. Income						
a) Revenue from operations	2016.71	2016.71	1909.42	1700.87	7798.80	
b) Other Income	70.58	67.94	238.05	110.14	506.52	
1. Total income from operations (net) (a+b)	2087.30	2084.65	2147.47	1811.01	8305.32	
2. Expenses						
a) Cost of materials consumed	1,320.89	1,320.89	1,130.96	856.26	4645.84	
b) Purchases of stock-in-trade	50.20	50.20	26.26	20.67	84.66	
c) Changes in inventories of finished products, work in progress and stock in trade	(121.27)	(121.27)	171.56	136.11	152.61	
d) Employee benefits expense	281.34	281.34	382.55	262.11	1204.10	
e) Finance costs	8.96	8.96	6.90	18.13	56.87	
f) Depreciation and amortization expense	75.66	25.09	24.31	27.62	109.57	
g) Other expenses:						
i) Manufacturing & Operating	98.82	98.82	111.43	99.39	425.85	
ii) Others	251.45	243.03	391.58	205.30	1185.37	
Total expenses	1966.06	1907.07	2245.55	1625.60	7864.87	
3. Profit/(Loss) before exceptional items and extraordinary items and tax	121.24	177.58	-98.08	185.41	440.45	
4. Exceptional Items						
5. Profit/(Loss) before tax	121.24	177.58	-98.08	185.41	440.45	
6. Tax (Expenses)/ Benefit						
Current tax	-	-	(125.00)	18.73	(125.00)	
Deffered tax	-	-	(59.02)	-	(59.02)	
Tax Related to Earlier Years	-	-	18.72	-	16.71	
7. Net Profit/(Loss) for the period from continuing operations	121.24	177.58	-263.38	204.14	273.14	
8. Net Profit/(Loss) for the period from discontinuing operations before tax						
9. Tax Expenses on discontinuing operations						
10. Net Profit/(Loss) for the period from discontinuing operations after tax						
11. Net Profit/(Loss) for the period	121.24	177.58	-263.38	204.14	273.14	
12. Other Comprehensive Income						
(i) (a) Items that will not be reclassified to profit or loss	1.37	1.37	(6.73)	-	(6.60)	
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	
Total Other comprehensive (loss)/ income (net of tax)	1.37	1.37	(6.73)	-	(6.60)	
9. Total comprehensive income for the period (7+8)	122.61	178.95	-270.11	204.14	266.54	
10. Paid-up equity share capital (Face Value ₹10 Each)	2104.06	2104.06	2104.06	2104.06	2104.06	
11. Face value of Equity	10.00	10.00	10.00	10.00	10.00	
11. Other equity (excluding revaluation reserve)					8223.49	
12. Debenture Redemption Reserve						
13. Basic and Diluted Earnings per share after extraordinary items, (In Rs.)	0.58	0.85	(1.28)	0.97	1.27	

Notes -

- The above results have been subjected to Limited Review by the Statutory Auditors were reviewed by Audit Committee and have been approved by the Board of Directors at its meeting today.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Provision for Tax may not have been made for the partial/ unaudited periods.
- The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.
- During the quarter dispute has arose in connection with advance for investment in property situated at Kibe Compound, amounting to Rs. 1.61 crore. The same is pending before the Additional District Judge, District Court, Indore

For ALPA LABORATORIES LIMITED
PARESH CHAWLA
MANAGING DIRECTOR
DIN NO.00520411

